Cipla recalls 1.40 lakh vials of Levalbuterol Inhalation Solution in US

22 May 2015 Evaluate

Cipla is recalling in the US market 1,40,625 vials of Levalbuterol Inhalation Solution used for relieving shortness of breath and coughing caused by asthma and chronic obstructive pulmonary disease. The drug major is recalling the drug for ‘failed impurities and degradation specifications’.

The vials were manufactured by Cipla at its Pithampur manufacturing facility, near Indore, for Princeton-based Dr Reddy's Laboratories Inc. The nationwide recall has been initiated by the company on April 24 this year.

The recall of the drugs has been initiated under Class-III which FDA defined as ‘a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences’.

Cipla, which has presence in over 150 countries, sells more than 2,000 products across various therapeutic categories. The company has 34 manufacturing facilities that make active pharmaceutical ingredients (APIs) and formulations.

Cipla Share Price

1517.20 5.10 (0.34%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×